Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Abstract Introduction Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. We evaluated the...

Full description

Saved in:
Bibliographic Details
Main Authors: Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-11-01
Series:Dermatology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s13555-024-01292-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594961364680704
author Richard B. Warren
Lev Pavlovsky
Antonio Costanzo
Michael Bukhalo
Neil J. Korman
Yu-Huei Huang
Georgios Kokolakis
Andreas Pinter
Nadia Ibrahim
Yanbing Zheng
Leonidas Drogaris
Vassilis Stakias
Ahmed M. Soliman
Simone Rubant
Diamant Thaçi
author_facet Richard B. Warren
Lev Pavlovsky
Antonio Costanzo
Michael Bukhalo
Neil J. Korman
Yu-Huei Huang
Georgios Kokolakis
Andreas Pinter
Nadia Ibrahim
Yanbing Zheng
Leonidas Drogaris
Vassilis Stakias
Ahmed M. Soliman
Simone Rubant
Diamant Thaçi
author_sort Richard B. Warren
collection DOAJ
description Abstract Introduction Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. We evaluated the efficacy and safety of directly switching patients with moderate-to-severe plaque psoriasis and a suboptimal response to interleukin (IL)-17 inhibitors (secukinumab or ixekizumab) to risankizumab. Methods This 52-week, phase 3b study enrolled patients (≥ 18 years) with moderate-to-severe plaque psoriasis who had previously been treated with the recommended dose of secukinumab or ixekizumab for ≥ 6 months but did not achieve an optimal response (static Physician's Global Assessment [sPGA] 2/3; body surface are [BSA] 3– < 10%). Patients received subcutaneous risankizumab (150 mg) without washout. The primary endpoint was the proportion of patients achieving sPGA of 0/1 at week 16. Secondary endpoints included sPGA 0/1 at week 52, sPGA 0, Dermatology Life Quality Index (DLQI) 0/1, and Psoriasis Symptoms Scale (PSS) 0 at weeks 16 and 52. Safety was monitored throughout the study. Results The study included 244 patients. sPGA 0/1 was achieved by 57.4% and 62.3% at week 16 and 52. At week 16, sPGA 0, DLQI 0/1, and PSS 0 were achieved by 20.5%, 40.2%, and 20.9%, respectively. At week 52, these proportions increased to 27.1% for sPGA 0, 47.2% for DLQI 0/1, and 27.5% for PSS 0. Most frequently reported adverse events (reported in ≥ 5% of patients) in risankizumab-treated patients were COVID-19 infection (8.6%) and nasopharyngitis (5.7%). No new safety signals were observed. Conclusions Directly switching to risankizumab improved outcomes and QoL in patients with moderate-to-severe psoriasis who had suboptimal responses to anti-IL-17 inhibitors (secukinumab or ixekizumab). The safety results are consistent with previously reported safety of risankizumab. This study supports the efficacy of risankizumab in patients previously treated with biologics, including IL-17 inhibitors, and suggests a direct switch to risankizumab for improved clinical outcomes and QoL. Clinical Trials ClinicalTrials.gov identifier: NCT04102007. Graphical Abstract
format Article
id doaj-art-34355c7facb14d3c80d5e8afaa8abaab
institution Kabale University
issn 2193-8210
2190-9172
language English
publishDate 2024-11-01
publisher Adis, Springer Healthcare
record_format Article
series Dermatology and Therapy
spelling doaj-art-34355c7facb14d3c80d5e8afaa8abaab2025-01-19T12:11:04ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722024-11-0114123273329010.1007/s13555-024-01292-zEfficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) StudyRichard B. Warren0Lev Pavlovsky1Antonio Costanzo2Michael Bukhalo3Neil J. Korman4Yu-Huei Huang5Georgios Kokolakis6Andreas Pinter7Nadia Ibrahim8Yanbing Zheng9Leonidas Drogaris10Vassilis Stakias11Ahmed M. Soliman12Simone Rubant13Diamant Thaçi14The Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Salford Royal NHS Foundation TrustSackler Faculty of Medicine, Tel Aviv UniversityDepartment of Biomedical Sciences, Humanitas UniversityArlington DermatologyDepartment of Dermatology, University Hospitals Cleveland Medical Center and Case Western Reserve UniversityDepartment of Dermatology, Linkou Branch, Chang Gung Memorial HospitalPsoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Dermatology, University Hospital Frankfurt am MainAbbVie Inc.AbbVie Inc.AbbVie Inc.AbbVie Inc.AbbVie Inc.AbbVie DeutschlandInstitute and Comprehensive Center Inflammation Medicine, University of LübeckAbstract Introduction Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. We evaluated the efficacy and safety of directly switching patients with moderate-to-severe plaque psoriasis and a suboptimal response to interleukin (IL)-17 inhibitors (secukinumab or ixekizumab) to risankizumab. Methods This 52-week, phase 3b study enrolled patients (≥ 18 years) with moderate-to-severe plaque psoriasis who had previously been treated with the recommended dose of secukinumab or ixekizumab for ≥ 6 months but did not achieve an optimal response (static Physician's Global Assessment [sPGA] 2/3; body surface are [BSA] 3– < 10%). Patients received subcutaneous risankizumab (150 mg) without washout. The primary endpoint was the proportion of patients achieving sPGA of 0/1 at week 16. Secondary endpoints included sPGA 0/1 at week 52, sPGA 0, Dermatology Life Quality Index (DLQI) 0/1, and Psoriasis Symptoms Scale (PSS) 0 at weeks 16 and 52. Safety was monitored throughout the study. Results The study included 244 patients. sPGA 0/1 was achieved by 57.4% and 62.3% at week 16 and 52. At week 16, sPGA 0, DLQI 0/1, and PSS 0 were achieved by 20.5%, 40.2%, and 20.9%, respectively. At week 52, these proportions increased to 27.1% for sPGA 0, 47.2% for DLQI 0/1, and 27.5% for PSS 0. Most frequently reported adverse events (reported in ≥ 5% of patients) in risankizumab-treated patients were COVID-19 infection (8.6%) and nasopharyngitis (5.7%). No new safety signals were observed. Conclusions Directly switching to risankizumab improved outcomes and QoL in patients with moderate-to-severe psoriasis who had suboptimal responses to anti-IL-17 inhibitors (secukinumab or ixekizumab). The safety results are consistent with previously reported safety of risankizumab. This study supports the efficacy of risankizumab in patients previously treated with biologics, including IL-17 inhibitors, and suggests a direct switch to risankizumab for improved clinical outcomes and QoL. Clinical Trials ClinicalTrials.gov identifier: NCT04102007. Graphical Abstracthttps://doi.org/10.1007/s13555-024-01292-zPsoriasisEfficacySafetyRisankizumab
spellingShingle Richard B. Warren
Lev Pavlovsky
Antonio Costanzo
Michael Bukhalo
Neil J. Korman
Yu-Huei Huang
Georgios Kokolakis
Andreas Pinter
Nadia Ibrahim
Yanbing Zheng
Leonidas Drogaris
Vassilis Stakias
Ahmed M. Soliman
Simone Rubant
Diamant Thaçi
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Dermatology and Therapy
Psoriasis
Efficacy
Safety
Risankizumab
title Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
title_full Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
title_fullStr Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
title_full_unstemmed Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
title_short Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
title_sort efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab results from a phase 3b open label single arm aimm study
topic Psoriasis
Efficacy
Safety
Risankizumab
url https://doi.org/10.1007/s13555-024-01292-z
work_keys_str_mv AT richardbwarren efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT levpavlovsky efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT antoniocostanzo efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT michaelbukhalo efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT neiljkorman efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT yuhueihuang efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT georgioskokolakis efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT andreaspinter efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT nadiaibrahim efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT yanbingzheng efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT leonidasdrogaris efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT vassilisstakias efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT ahmedmsoliman efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT simonerubant efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy
AT diamantthaci efficacyandsafetyofrisankizumabinpatientswithpsoriasisshowingsuboptimalresponsetosecukinumaborixekizumabresultsfromaphase3bopenlabelsinglearmaimmstudy